Compare GETY & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GETY | BCYC |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 490.7M | 360.7M |
| IPO Year | 2022 | 2019 |
| Metric | GETY | BCYC |
|---|---|---|
| Price | $0.93 | $5.28 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $3.78 | ★ $13.90 |
| AVG Volume (30 Days) | ★ 1.5M | 593.0K |
| Earning Date | 05-11-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $926,244,000.00 | N/A |
| Revenue This Year | $0.37 | N/A |
| Revenue Next Year | $1.49 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 0.82 | N/A |
| 52 Week Low | $0.67 | $4.24 |
| 52 Week High | $3.21 | $9.55 |
| Indicator | GETY | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 61.14 | 57.90 |
| Support Level | $0.71 | $5.03 |
| Resistance Level | $0.93 | $5.90 |
| Average True Range (ATR) | 0.05 | 0.25 |
| MACD | 0.02 | 0.09 |
| Stochastic Oscillator | 87.49 | 90.99 |
Getty Images Holdings Inc. is a visual content creator and marketplace that offers a full range of content solutions. Through its Getty Images, Stock, and Unsplash brands, websites, and APIs, it serves customers around the world by allowing them to discover, purchase, and share visual content from photographers, illustrators, image partners, and videographers. The company generates a majority of its revenue through subscriptions, offering various subscription products on the Getty Images, iStock, and Unsplash websites. It operates and manages one operating segment, which is the business of developing and commercializing visual content. Geographically, the company generates maximum revenue from the Americas, followed by Europe, the Middle East and Africa, and the Asia-Pacific region.
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.